Literature DB >> 17709227

Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients.

S Bonvalot1, H Eldweny, V Haddad, F Rimareix, G Missenard, O Oberlin, D Vanel, P Terrier, J Y Blay, A Le Cesne, C Le Péchoux.   

Abstract

OBJECTIVE: To evaluate the impact of surgery as first-line treatment on event-free survival (EFS) of primary aggressive fibromatosis. PATIENTS AND METHODS: Treatments were categorized into: surgery with or without radiotherapy and nonsurgical strategies with systemic treatment alone or wait and see policy. Eighty-nine patients had initial resection of their primary tumour followed by postoperative radiotherapy in 13 cases. Twenty-three did not undergo surgery but received systemic treatment or watch and wait policy.
RESULTS: Median follow-up was 76 months. Overall 3 years EFS was 49%. In the univariate analysis, patients with microscopically complete surgery had a similar outcome to patients in the no-surgery group (3 years EFS of 65% and 68%, respectively). Gender, age, tumour size, treatment period and strategy (surgery versus no-surgery) were not statistically significant. Quality of resection according to margins and the tumour site were the only prognostic factors. There was a significant correlation between tumour site and quality of surgery (p=0.0002).
CONCLUSIONS: A subset of patients with extra-abdominal fibromatosis could be managed with a nonaggressive policy, as growth arrest concerned 2/3 of nonoperated patients. When surgery is finally necessary, it should be performed with the aim of achieving negative margins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709227     DOI: 10.1016/j.ejso.2007.06.006

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  67 in total

1.  Contralateral recurrence of aggressive fibromatosis in a young woman: A case report and review of the literature.

Authors:  Christopher J Schmoyer; Harmar D Brereton; Eric W Blomain
Journal:  Oncol Lett       Date:  2015-05-18       Impact factor: 2.967

2.  Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.

Authors:  Yoshihiro Nishida; Akira Kawai; Junya Toguchida; Akira Ogose; Keisuke Ae; Toshiyuki Kunisada; Yoshihiro Matsumoto; Tomoya Matsunobu; Kunihiko Takahashi; Kazuki Nishida; Toshifumi Ozaki
Journal:  Int J Clin Oncol       Date:  2019-07-22       Impact factor: 3.402

3.  Low-dose chemotherapy with methotrexate and vinblastine for patients with desmoid tumors: relationship to CTNNB1 mutation status.

Authors:  Yoshihiro Nishida; Satoshi Tsukushi; Hiroshi Urakawa; Shunsuke Hamada; Eiji Kozawa; Kunihiro Ikuta; Yuichi Ando; Naoki Ishiguro
Journal:  Int J Clin Oncol       Date:  2015-04-22       Impact factor: 3.402

Review 4.  A guide to oncological management of soft tissue tumours of the abdominal wall.

Authors:  K J Williams; A J Hayes
Journal:  Hernia       Date:  2013-09-17       Impact factor: 4.739

Review 5.  Desmoid-Type Fibromatosis: Who, When, and How to Treat.

Authors:  Javier Martínez Trufero; Isabel Pajares Bernad; Irene Torres Ramón; Jorge Hernando Cubero; Roberto Pazo Cid
Journal:  Curr Treat Options Oncol       Date:  2017-05

6.  Prognostic factors for second recurrence after surgical resection of recurrent desmoid-type fibromatosis.

Authors:  Justin M M Cates
Journal:  Pathol Oncol Res       Date:  2015-04-29       Impact factor: 3.201

7.  Desmoid tumors: clinical features and outcome of an unpredictable and challenging manifestation of familial adenomatous polyposis.

Authors:  Fábio Guilherme Campos; Carlos Augusto Real Martinez; Marleny Novaes; Sérgio Carlos Nahas; Ivan Cecconello
Journal:  Fam Cancer       Date:  2015-06       Impact factor: 2.375

8.  MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumours.

Authors:  Firouzeh Kamali; Wei-Lien Wang; B A Guadagnolo; Patricia S Fox; Valerae O Lewis; Alexander J Lazar; Anthony P Conley; Vinod Ravi; Mohammad Toliyat; Harshad S Ladha; Brian P Hobbs; Behrang Amini
Journal:  Br J Radiol       Date:  2015-11-18       Impact factor: 3.039

9.  High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management.

Authors:  J Dômont; S Salas; L Lacroix; V Brouste; P Saulnier; P Terrier; D Ranchère; A Neuville; A Leroux; L Guillou; R Sciot; F Collin; A Dufresne; J-Y Blay; A Le Cesne; J-M Coindre; S Bonvalot; J Bénard
Journal:  Br J Cancer       Date:  2010-03-02       Impact factor: 7.640

Review 10.  A systematic review of active treatment options in patients with desmoid tumours.

Authors:  X Yao; T Corbett; A A Gupta; R A Kandel; S Verma; J Werier; M Ghert
Journal:  Curr Oncol       Date:  2014-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.